Presentation is loading. Please wait.

Presentation is loading. Please wait.

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Published byIvan Widjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between."— Presentation transcript:

1 Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm.
Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. The boxes and lines indicate the relative risks (RRs) and their CIs. Weights are from random-effects analysis. The size of the box indicates the relative weight of each estimate. Diamonds indicate the combined RRs. Shiv Kumar Agarwal et al. Open Heart 2015;2:e000317 ©2015 by British Cardiovascular Society

Download ppt "Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between."

Similar presentations

Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Relative risk of major events with atenolol vs placebo

Relative risk of major events with atenolol vs placebo
Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.
Ashish Shukla et al. JACEP 2015;1:41-51

Ashish Shukla et al. JACEP 2015;1:41-51
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Fung TT, et al. Circulation 2009;119:

Fung TT, et al. Circulation 2009;119:
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.
Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)
Berger JS, et al. JAMA 2009;301:1909-19.

Berger JS, et al. JAMA 2009;301:
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies  Geoffrey.

Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies  Geoffrey.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
(A) Meta-analysis of repeat revascularisation in randomised trials.

(A) Meta-analysis of repeat revascularisation in randomised trials.
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Similar presentations

Ads by Google